Agentix Corp.: financial analysis
Ratios worked out from 10 fiscal years of Agentix Corp.'s statements, compared with 665 companies in Biotechnology.
Agentix Corp. scorecard#
Passes 1 of the 7 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.01 vs -0.01Diluted EPS -0.01 in fiscal 2025 against -0.01 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$0 MNet income -$0 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.0×Current ratio 0.00 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-5.6×Operating income -5.6 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year0.0%Diluted shares down 0.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Net loss of $0 million, the 5th loss-making year in a row.
- Shareholders' equity is negative: -$4 million.
- Operating income covers the interest bill only -5.6 times.
- Liabilities due within a year exceed current assets (current ratio 0.00).
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets rosenot on file
- Cash from operations exceeds profityes
- Long-term debt fell against assetsnot on file
- Current ratio roseno
- No new shares issuedyes
- Gross margin rosenot on file
- Asset turnover rosenot on file
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Return on equity | — | — | — | — | — | -61.0% | — | |
| Return on assets | -980.0% | -542.9% | -318.9% | -978.6% | — | -44.4% | 0% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Interest cover | -5.62× | -12.75× | -37.00× | — | — | -22.77× | 75% | |
| Current ratio | 0.00× | 0.03× | 0.04× | 0.10× | 0.02× | 4.39× | 0% | |
| Equity share of assets | — | — | — | -865.4% | — | 64.7% | — |
How each figure is worked out#
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
Source: Agentix Corp.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 665 companies in Biotechnology that Agentix Corp. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Agentix Corp.